Drug intelligence / Profile preview

SGL0010

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

SGL0010 (also known as TS-033) is an orally active dual inhibitor of sodium-dependent glucose cotransporters 1 and 2 (SGLT1 and SGLT2) that was developed by Taisho Pharmaceutical for the treatment of type 1 and type 2 diabetes mellitus. By inhibiting SGLT1 and SGLT2, SGL0010 suppresses glucose reabsorption in the renal proximal tubules, thereby enhancing urinary glucose excretion and reducing blood glucose levels. SGL0010 reached Phase II clinical trials in Japan and the United States, but its development was discontinued by Taisho Pharmaceutical in October 2008.

Targets

SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on SGL0010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGL0010.